| Background and Purpose Schizophrenia is a severe mental illness characterized by hallucinations,delusions,and abnormal speech and behavior,as well as negative symptoms such as decreased volition and flat emotions.At present,the main treatment method is drug therapy.While drug therapy brings about improvement of the condition,it is also accompanied by a large number of side effects.Observation of clinical work has found that while schizophrenia patients who use ammonia sulfonate have a significant effect,they are also accompanied by weight gain,elevated prolactin levels,extrapyramidal reactions and other adverse reactions,especially,compared with other antipsychotic drugs.In contrast,patients taking amisulpride more often have bradycardia during ECG examinations.A review of the relevant literature also found a number of case reports of bradycardia caused by amisulpride,but there is no research on systematically observing changes in patients’ heart rate before and after medication.The purpose of this research is to clarify the efficacy and clinical safety of amisulpride in patients with schizophrenia,and to explore the relationship between amisulpride and bradycardia by observing the changes in the heart rate of patients before and after medication,so as to provide a certain reference for clinical medication selection.Object and Methods The subjects of the study were patients with schizophrenia who were treated in the outpatient and inpatient treatments of the Mental Health Center of Shantou University from June 2020 to February 2021.Before medication,basic information collection,PANSS scale assessment,and baseline blood lipid,blood glucose,prolactin,insulin,and heart rate were collected for patients who met the inclusion criteria.Following an8-week observation,the patient was treated with amisulpride tablets alone.The initial therapeutic dose was 200 mg/d and gradually increased to 800 mg/d.In the second,fourth,sixth,and eighth week PANSS scale assessment,blood biochemistry,blood routine,prolactin,insulin,electrocardiogram,electroencephalogram were performed every week.Results1.Clinical efficacy: Compared with the scores of the baseline level before treatment,the patients’ PANSS total score,negative symptom score,and positive symptom score decreased significantly after 8 weeks of treatment,and there were significant differences(p<0.01).2.Blood lipids: The level of triglycerides is higher than before treatment,but it is still within the medical normal range.3.Blood glucose: Compared with the baseline level before treatment,there is no significant difference in blood glucose level.4.Prolactin: Amisulpride significantly increased prolactin.Compared with the baseline level,prolactin levels increased significantly at 2,4,6,and 8 weeks,with a significant difference(p<0.01).5.Heart rate: The patient’s heart rate decreased during amisulpride,compared with the baseline level(72.93±6.39),the patient’s heart rate decreased significantly(68.97±8.20)after treatment,with a significant difference(p<0.01).ConclusionIn all patients in this study,the PANSS total score,negative symptom score,and positive symptom score before and after treatment were significantly reduced,suggesting that amisulpride has a significant effect on schizophrenia.While the patient’s symptoms were improved,the patient’s HDL,cholesterol,and blood glucose did not change significantly,and triglycerides were significantly increased,but they were still within the medical normal range,suggesting that amisulpride has little effect on blood lipids and almost no effect on blood glucose.The prolactin level of the study subjects increased significantly after treatment,and the results indicated that prolactin increased significantly in the second week after the use of amisulpride,suggesting that amisulpride can rapidly increase prolactin.The patient’s heart rate was significantly reduced before and after treatment,and of the 30 patients included in the study,8 had bradycardia during treatment,suggesting that amisulpride has the side effect of lowering the heart rate. |